AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Prevalence of Statin Use for Primary and Secondary ASCVD Prevention Among Statin-Eligible US Adults with Compensated Advanced Chronic Liver Disease: An NHANES Study

By DOSHI A, Mody M, Patel J et al.

Background: Cardiovascular disease is a major cause of morbidity among adults with chronic liver disease. Although statins are recommended for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), their use among adults with compensated advanced chronic liver disease (cACLD) is not well characterized. Research Question: What is prevalence of statin use for ASCVD prevention among statin-eligible adults with cACLD? Methods: We performed a cross-sectional analysis of adults in NHANES 2017-March 2020. cACLD was identified using vibration-controlled transient elastography per Baveno VII criteria and categorized as possible cACLD (liver stiffness measurement [LSM] 10-14.9 kPa) or highly suggestive cACLD (LSM >/= 15 kPa), consistent with prior literature. Statin eligibility was defined by clinical ASCVD, LDL-C >/= 190 mg/dL, diabetes mellitus (among adults aged 40-75 years), or PREVENT-estimated 10-year ASCVD risk >/=5%. Statin use was identified from prescription medication data. NHANES survey weights were applied to generate US population estimates. Survey-adjusted statistical tests were used to assess differences in statin utilization across clinical and demographic subgroups. Results: Among 568 U.S. adults with cACLD, 37.7% (95% CI, 32.8-42.8%), corresponding to an estimated 5.27million adults, met indications for statin therapy. Statin-eligible individuals had a median age of 64 years (IQR, 57-72); 64.9% were male, 66.6% were Non-Hispanic White, 15.2% Hispanic, 9.8% Non-Hispanic Black, and 8.4% Asian/Multi-racial. Hypertension was present in 80.4%, obesity in 78.6%, diabetes mellitus in 79.9%, current smoking in 23.3%, established ASCVD in 48.9%, and LDL-C ≥190 mg/dL in 4.6%. Median AST was 22 IU/L (IQR, 18-31) and ALT was 21 IU/L (IQR, 15-33) (Table 1) . Overall, only 49.5% (95% CI, 37.5-61.5%) of statin-eligible adults with cACLD were receiving statin therapy. Statin use was significantly higher among those with established ASCVD compared to those without (65.5% vs. 34.1%, p<0.001). Statin use did not differ by cACLD severity, sex, or race/ethnicity. Statin use varied by BMI category, with use highest among overweight adults (64.4%), followed by obese adults (41.6%) and normal/underweight adults (25.3%), showing a trend toward significance (p=0.07) (Table 2) . Conclusion: In this nationally representative NHANES analysis, approximately half of statin-eligible U.S. adults with cACLD were not receiving statin therapy. Underuse was most pronounced among adults without established ASCVD and varied by BMI category, with the lowest statin use observed among normal/underweight adults and persistently low use among adults with obesity. These findings highlight important gaps in ASCVD prevention among adults with cACLD and support targeted efforts to improve implementation of guideline-directed preventive therapy.

doi.org/10.1161/circ.154.suppl_1.9805Populations

AgingResearch.News